Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2020 20:22 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
December 07, 2020 16:01 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Commencement of Public Offering of Common Stock

SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
December 05, 2020 12:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting

– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a...
October 29, 2020 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Third Quarter 2020 Financial Results

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
May 29, 2020 08:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

– Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC – – Outcomes with approved therapies are poor, with reported median OS of 5-8...
February 19, 2020 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
February 18, 2020 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results

SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
August 12, 2019 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
August 07, 2019 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
August 01, 2019 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update

- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – –...

Next Page keyboard_arrow_right